Drug Trial Radar · NCT06895343
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Apr 3, 2025
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-701Drug
Subcutaneous
PlaceboDrug
Subcutaneous
ABBV-701Drug
IV Infusion
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 47 weeks
- Maximum Plasma Concentration (Cmax) of ABBV-701Time frame: Up to approximately 47 weeks
- Time to Cmax (Tmax) of ABBV-701Time frame: Up to approximately 47 weeks
- Apparent terminal phase elimination rate constant (β) of ABBV-701Time frame: Up to approximately 47 weeks
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-701Time frame: Up to approximately 47 weeks
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-701Time frame: Up to approximately 47 weeks
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-701Time frame: Up to approximately 47 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CenExel ACT- Anaheim Clinical Trials /ID# 278431
Anaheim, California
Acpru /Id# 273354
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.